FDA Accepts Sun Pharma's Application to Expand ILUMYA Use for Psoriatic Arthritis

Sun Pharmaceutical Industries has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab) to treat adults with active psoriatic arthritis. Currently approved for moderate-to-severe plaque psoriasis in multiple countries, ILUMYA's expanded indication aims to address joint symptoms associated with psoriatic disease. The FDA's decision is expected by October 29, 2026, supported by Phase 3 clinical trial data demonstrating efficacy and safety.